▲ +51.86% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Myovant Sciences in the last 3 months. The average price target is $31.57, with a high forecast of $55.00 and a low forecast of $24.00. The average price target represents a 51.86% upside from the last price of $20.79.
The current consensus among 7 contributing investment analysts is to hold stock in Myovant Sciences. This rating has held steady since April 2021, when it changed from a Buy consensus rating.
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.